Skip to content

Platelets Activation in Brain Neoplasms

Observation of Platelets in Primary and Secondary Tumors of the Central Nervous System and Association With Survival: a Prospective Cohort Study

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05049148
Acronym
Platon
Enrollment
50
Registered
2021-09-17
Start date
2022-10-27
Completion date
2029-10-31
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Platelets, Brain Neoplasms, Glioma, Inflammation

Keywords

Platelets activation

Brief summary

Platelets are primarily known for their central role in primary hemostasis. However, they are increasingly recognized for their participation in various non-hemostatic processes, such as cancer progression and clinical expression. Experimental and clinical data indicate that the involvement of platelets in the pathophysiology of cancer goes far beyond the realm of cancer-associated thrombosis. Several experimental studies have shown that platelets can promote the metastatic process by various mechanisms. However, while it has been shown in vitro that direct contact with platelets initiates tumor cells for metastasis, it remains unclear whether such contacts occur in solid tumors. In addition to their ability to promote metastasis, platelets have been shown to stimulate angiogenesis and play a crucial role in lymphangiogenesis. Considering that blood vessels, lymphatics and immune cells are major components of the tumor ecosystem, our hypothesis is that platelets contribute to the development and / or regulation of the tumor microenvironment. This is because platelets stabilize tumor blood vessels by permanently repairing vascular damage caused by immune cells infiltrating tumors. Targeting platelets destabilizes tumor vessels, causing intra-tumor hemorrhage, which allows intra-tumor accumulation of intravenously administered anti-tumor drugs such as paclitaxel and improves their efficacy. Studies have also reported the role of platelets in several pathogenic mechanisms of cancer: thrombocytosis is a paraneoplastic syndrome which suggests a poor prognosis in patients with solid tumors; a negative correlation between the platelet count and the response to chemotherapy has been reported in several types of cancer; histological analyzes of esophageal cancer suggested a possible association between the presence of platelets in the tumor stroma and the level of tumor lymphangiogenesis and lymphovascular invasion; finally, a recent study reported the expression of one of the main targets of immunotherapies, PD-L1, on the platelets of patients suffering from different types of solid cancers. All of these data support our hypothesis that platelets are components and / or regulators of the tumor microenvironment and therefore potential targets for the improvement of anti-tumor therapies. In this context, the objectives of our project are to determine whether platelets are components of the microenvironment of tumors of the central nervous system, and to study the possible correlations between the intratumoral presence of platelets and the evolution of patients with central nervous system tumors

Detailed description

This is a descriptive study that did not include any intervention other than tumor tissue preservation and blood sampling.

Interventions

OTHERPlatelet count in excised tumors

Tumors excised in patients requirering a brain or medullary surgery will be assess to determine their platelet count.

Sponsors

Fondation Ophtalmologique Adolphe de Rothschild
Lead SponsorNETWORK

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient to undergo excision or biopsy of a brain or medullary tumor * Patient over 18 years old * Express consent to participate in the study * Affiliate member of the Social Security system

Exclusion criteria

* Tumor sample volume not allowing the performance of additional analyzes * Patient benefiting from a legal protection measure * Pregnant or breastfeeding woman

Design outcomes

Primary

MeasureTime frameDescription
Platelet detection in excised brain/medurally tumors1 hourbiopsy: Presence of neo-vessels

Countries

France

Contacts

Primary ContactAmélie YACHITZ, MD
ayavchitz@for.paris(0)148036454
Backup ContactVivien VASSEUR
vvasseur@for.paris(0)148036440

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026